Navigation Links
Northern Ireland company makes major breakthrough in cancer treatment
Date:11/8/2011

The findings of Almac scientists' research have been published in the online version of the Journal of Clinical Oncology (JCO) ahead of the print edition of the journal. The JCO is the peer-reviewed publication of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

Colon cancer is the third most common cancer in the US. Over 100,000 patients are diagnosed each year and around one quarter of these patients are diagnosed with stage 2 of the disease.

Stage 2 colon cancer has a relatively good prognosis with around 80% of patients cured by surgery but the disease will recur in the remaining 20% within five years.

Although the 20% of patients in which the cancer recurs may benefit from chemotherapy there is currently no test which doctors can use to help identify them.

The JCO report gives detail on the development and validation of a prognostic test designed by Almac, ColDX, specifically developed to identify high risk patients who may benefit from additional therapy.

Professor Paul Harkin, President and Managing Director of Almac's Diagnostic business and Professor of Molecular Oncology at Queen's University Belfast said:

"We have used complex technologies designed in Craigavon, Northern Ireland, to examine tumour samples from around the world to identify a genetic signature which tell us the likelihood of stage 2 colon cancer recurring. This technology will make it much more straightforward for doctors to identify high risk patients who may benefit from chemotherapy.

"Our highly novel test represents a significant breakthrough in how colon cancer can be managed. We believe it has the potential to change clinical practice and save the lives of some cancer patients. "Almac is committed to research which improves the health of people around the world and this is just one example of how we are working to achieve that."

Almac scientists including, Professor Richard Kennedy, Dr Max Bylesjo, Dr Peter Kerr, Dr Timothy Davison and Dr Vitali Proutski were involved in the research.

The test was developed using Almac's proprietary discovery technology and using clinical patient samples from around 14 clinical sites across the world including Queen's University Belfast.

Professor Patrick Johnston, Dean, School of Medicine, Dentistry and Biomedical Sciences at Queen's, said:

"We are pleased to have been able to play a role in helping Almac to develop this groundbreaking technology which we hope could save many lives in the future. Both Queen's and Almac are working tirelessly in advancing cancer research and treatments."

Following further external validation and commercialisation the test could be available to UK patients within a couple of years and potentially even sooner in the US.


'/>"/>
Contact: Andrea Clements
andrea.clements@jprni.com
JPR
Source:Eurekalert  

Related medicine news :

1. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
2. Northern Illinois Proton Center on the Verge of Major Medical Breakthrough
3. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
4. Does the weather cause northerners to get more prostate cancer?
5. Lice Control™ Incorporates the Revolutionary LouseBuster™ Device in its Head Lice Removal Arsenal in Northern California
6. PEDEGO ELECTRIC BIKES Partners with Mike's Bikes in Northern California for Bike to Work Week
7. Infant and Young Child Self-Rescue(TM) Swimming Program Coming to Northern Colorado
8. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
9. Study focuses on mephedrone use in Northern Ireland post-ban
10. Child soldier trauma in Uganda shares similarities with Northern Ireland
11. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Northern Ireland company makes major breakthrough in cancer treatment
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: